News
Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...
2d
Zacks.com on MSNPfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...
6d
Benzinga on MSNPfizer CEO Says Trump Tariff Uncertainty Is Holding Back U.S. Investments in R&D and ManufacturingPfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S.
Pharmaceutical imports to the U.S. surged in March as drugmakers stocked up ahead of potential U.S. tariffs on their products ...
Latin Times on MSN6d
Pfizer CEO Tariff Uncertainty Hinders U.S. InvestmentsPfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is ...
Pfizer CEO Albert Bourla said Tuesday that uncertainty surrounding President Donald Trump’s proposed pharmaceutical tariffs is discouraging the company from making additional investments in U.S.
Pharmaceutical imports to the US surged in March as drugmakers stocked up ahead of potential tariffs on their products, which ...
President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the ...
Pfizer has promoted Albert Bourla, seen as a likely successor to incumbent CEO Ian Read, to the newly-created role of chief operating officer. The move could help Read focus on long-term strategy ...
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results